Therapeutic antibodies have revolutionized the treatment of cancer and autoimmune diseases. Today, a central challenge for the biotechnology industry is finding effective methods to identify novel therapeutic antibodies. BioInvent International AB recently established the F.I.R.S.T technology, which enables identification of antibodies that attack a specific cell type. Yet, identification of the targets of selected antibody candidates found by function-first approaches remains a major bottleneck. Combining the latest genomics technologies, we here explore an innovative method to accelerate the target identification process for therapeutic antibody candidates identified using function-first approaches.

This project is carried out in strong research environments at BioInvent International AB and Lund University, and is supervised by a team of investigators with a strong track record in the field. We aim to produce an innovative approach capable of dramatically accelerating the development of novel therapeutic antibodies towards cancer and autoimmune disorders.